| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10004349 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10015578 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10006128 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10016062 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028498 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028499 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10021267 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028500 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10038364 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10040827 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ALK |
|---|---|
| DrugBank ID | DB12141 |
| Drug Name | Gilteritinib |
| Target ID | BE0000359 |
| UniProt ID | Q9UM73 |
| Regulation Type | inhibitor |
| PubMed IDs | 27775694; 26279055; 28516360 |
| Citations | Antar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A: Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2017 Mar;52(3):344-351. doi: 10.1038/bmt.2016.251. Epub 2016 Oct 24.@@Thom C: Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. Future Oncol. 2015 Sep;11(18):2499-501. doi: 10.2217/fon.15.188. Epub 2015 Aug 17.@@Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S: Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpiperidines |
| SMILES | CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3301622 |
